AI-Driven Antibody Platform Will Unlock Major Aesthetic And Women’s Health Markets

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

18 Dec 25

Updated

24 Jul 26

Views

Not Invested

Shared on 24 Jul 26

Fair value Increased 70%

ABSI: Hair Loss And Endometriosis Readouts Will Drive The Next Phase

Wall Street is getting more upbeat on Absci after early trial results suggest its lead drug for hair loss is well tolerated, and the company lines up more funding to keep moving. The next big swing factor is whether upcoming trial updates in hair loss and endometriosis back up that early promise.

3 views

Fair Value vs Share Price

US$17

vs US$6.959.4% undervalued

379.4%

Revenue growth

27.2%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Absci

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with slight risk.

Market capUS$1.2b

PB6.8x

Estimated Growth49.8%

Dividend YieldN/A

Full analysis

CEO & management

Sean McClain

CEO

3.3yrs

CEO Tenure

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.